(https://easl.eu/wp-content/uploads/2022/01/LCS-2022-Abstract-book-final.pdf).
For additional information, please contact
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
About fostroxacitabine bralpamide
Fostroxacitabine bralpamide (also named MIV-818) is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer. Fostroxacitabine bralpamide has completed a phase 1b monotherapy study, and a combination study in HCC was recently initiated.
About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are 42,000 patients diagnosed with primary liver cancer per year in the US and current five-year survival is 11 percent. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.
About
Collaborations and partnerships are important parts of
https://news.cision.com/medivir/r/biomarker-data-from-the-fostroxacitabine-bralpamide-phase-1-study-to-be-presented-at-the-easl-liver-,c3490352
https://mb.cision.com/Main/652/3490352/1523531.pdf
(c) 2022 Cision. All rights reserved., source